The microculture-kinetic (MiCK) assay: The role of a drug-induced apoptosis assay in drug development and clinical care

Linda Bosserman, Franklyn Prendergast, Roy Herbst, Martin Fleisher, Emery Salom, Steven Strickland, Anastasios Raptis, Allan Hallquist, Mathieu Perree, Swapnil Rajurkar, Misagh Karimi, Karl Rogers, Dirk Davidson, Carl Willis, Manuel Penalver, Howard Homesley, Matthew Burrell, Audrey Garrett, James Rutledge, Michael ChernickCary A. Presant

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

A drug-induced apoptosis assay, termed the microculture-kinetic (MiCK) assay, has been developed. Blinded clinical trials have shown higher response rates and longer survival in groups of patients with acute myelocytic leukemia and epithelial ovarian cancer who have been treated with drugs that show high apoptosis in the MiCK assay. Unblinded clinical trials in multiple tumor types have shown that the assay will be used frequently by clinicians to determine treatment, and when used, results in higher response rates, longer times to relapse, and longer survivals. Model economic analyses suggest possible cost savings in clinical use based on increased generic drug use and single-agent substitution for combination therapies. Two initial studies with drugs in development are promising. The assay may help reduce costs and speed time to drug approval. Correlative studies with molecular biomarkers are planned. This assay may have a role both in personalized clinical therapy and in more efficient drug development.

Original languageEnglish (US)
Pages (from-to)3901-3905
Number of pages5
JournalCancer Research
Volume72
Issue number16
DOIs
StatePublished - Aug 15 2012

Fingerprint

Apoptosis
Pharmaceutical Preparations
Clinical Trials
Generic Drugs
Economic Models
Drug Approval
Cost Savings
Acute Myeloid Leukemia
Therapeutics
Survival Rate
Biomarkers
Costs and Cost Analysis
Recurrence
Survival
Neoplasms
Ovarian epithelial cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bosserman, L., Prendergast, F., Herbst, R., Fleisher, M., Salom, E., Strickland, S., ... Presant, C. A. (2012). The microculture-kinetic (MiCK) assay: The role of a drug-induced apoptosis assay in drug development and clinical care. Cancer Research, 72(16), 3901-3905. https://doi.org/10.1158/0008-5472.CAN-12-0681

The microculture-kinetic (MiCK) assay : The role of a drug-induced apoptosis assay in drug development and clinical care. / Bosserman, Linda; Prendergast, Franklyn; Herbst, Roy; Fleisher, Martin; Salom, Emery; Strickland, Steven; Raptis, Anastasios; Hallquist, Allan; Perree, Mathieu; Rajurkar, Swapnil; Karimi, Misagh; Rogers, Karl; Davidson, Dirk; Willis, Carl; Penalver, Manuel; Homesley, Howard; Burrell, Matthew; Garrett, Audrey; Rutledge, James; Chernick, Michael; Presant, Cary A.

In: Cancer Research, Vol. 72, No. 16, 15.08.2012, p. 3901-3905.

Research output: Contribution to journalArticle

Bosserman, L, Prendergast, F, Herbst, R, Fleisher, M, Salom, E, Strickland, S, Raptis, A, Hallquist, A, Perree, M, Rajurkar, S, Karimi, M, Rogers, K, Davidson, D, Willis, C, Penalver, M, Homesley, H, Burrell, M, Garrett, A, Rutledge, J, Chernick, M & Presant, CA 2012, 'The microculture-kinetic (MiCK) assay: The role of a drug-induced apoptosis assay in drug development and clinical care', Cancer Research, vol. 72, no. 16, pp. 3901-3905. https://doi.org/10.1158/0008-5472.CAN-12-0681
Bosserman, Linda ; Prendergast, Franklyn ; Herbst, Roy ; Fleisher, Martin ; Salom, Emery ; Strickland, Steven ; Raptis, Anastasios ; Hallquist, Allan ; Perree, Mathieu ; Rajurkar, Swapnil ; Karimi, Misagh ; Rogers, Karl ; Davidson, Dirk ; Willis, Carl ; Penalver, Manuel ; Homesley, Howard ; Burrell, Matthew ; Garrett, Audrey ; Rutledge, James ; Chernick, Michael ; Presant, Cary A. / The microculture-kinetic (MiCK) assay : The role of a drug-induced apoptosis assay in drug development and clinical care. In: Cancer Research. 2012 ; Vol. 72, No. 16. pp. 3901-3905.
@article{c3f5687fd62946949668ee12317faf31,
title = "The microculture-kinetic (MiCK) assay: The role of a drug-induced apoptosis assay in drug development and clinical care",
abstract = "A drug-induced apoptosis assay, termed the microculture-kinetic (MiCK) assay, has been developed. Blinded clinical trials have shown higher response rates and longer survival in groups of patients with acute myelocytic leukemia and epithelial ovarian cancer who have been treated with drugs that show high apoptosis in the MiCK assay. Unblinded clinical trials in multiple tumor types have shown that the assay will be used frequently by clinicians to determine treatment, and when used, results in higher response rates, longer times to relapse, and longer survivals. Model economic analyses suggest possible cost savings in clinical use based on increased generic drug use and single-agent substitution for combination therapies. Two initial studies with drugs in development are promising. The assay may help reduce costs and speed time to drug approval. Correlative studies with molecular biomarkers are planned. This assay may have a role both in personalized clinical therapy and in more efficient drug development.",
author = "Linda Bosserman and Franklyn Prendergast and Roy Herbst and Martin Fleisher and Emery Salom and Steven Strickland and Anastasios Raptis and Allan Hallquist and Mathieu Perree and Swapnil Rajurkar and Misagh Karimi and Karl Rogers and Dirk Davidson and Carl Willis and Manuel Penalver and Howard Homesley and Matthew Burrell and Audrey Garrett and James Rutledge and Michael Chernick and Presant, {Cary A.}",
year = "2012",
month = "8",
day = "15",
doi = "10.1158/0008-5472.CAN-12-0681",
language = "English (US)",
volume = "72",
pages = "3901--3905",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - The microculture-kinetic (MiCK) assay

T2 - The role of a drug-induced apoptosis assay in drug development and clinical care

AU - Bosserman, Linda

AU - Prendergast, Franklyn

AU - Herbst, Roy

AU - Fleisher, Martin

AU - Salom, Emery

AU - Strickland, Steven

AU - Raptis, Anastasios

AU - Hallquist, Allan

AU - Perree, Mathieu

AU - Rajurkar, Swapnil

AU - Karimi, Misagh

AU - Rogers, Karl

AU - Davidson, Dirk

AU - Willis, Carl

AU - Penalver, Manuel

AU - Homesley, Howard

AU - Burrell, Matthew

AU - Garrett, Audrey

AU - Rutledge, James

AU - Chernick, Michael

AU - Presant, Cary A.

PY - 2012/8/15

Y1 - 2012/8/15

N2 - A drug-induced apoptosis assay, termed the microculture-kinetic (MiCK) assay, has been developed. Blinded clinical trials have shown higher response rates and longer survival in groups of patients with acute myelocytic leukemia and epithelial ovarian cancer who have been treated with drugs that show high apoptosis in the MiCK assay. Unblinded clinical trials in multiple tumor types have shown that the assay will be used frequently by clinicians to determine treatment, and when used, results in higher response rates, longer times to relapse, and longer survivals. Model economic analyses suggest possible cost savings in clinical use based on increased generic drug use and single-agent substitution for combination therapies. Two initial studies with drugs in development are promising. The assay may help reduce costs and speed time to drug approval. Correlative studies with molecular biomarkers are planned. This assay may have a role both in personalized clinical therapy and in more efficient drug development.

AB - A drug-induced apoptosis assay, termed the microculture-kinetic (MiCK) assay, has been developed. Blinded clinical trials have shown higher response rates and longer survival in groups of patients with acute myelocytic leukemia and epithelial ovarian cancer who have been treated with drugs that show high apoptosis in the MiCK assay. Unblinded clinical trials in multiple tumor types have shown that the assay will be used frequently by clinicians to determine treatment, and when used, results in higher response rates, longer times to relapse, and longer survivals. Model economic analyses suggest possible cost savings in clinical use based on increased generic drug use and single-agent substitution for combination therapies. Two initial studies with drugs in development are promising. The assay may help reduce costs and speed time to drug approval. Correlative studies with molecular biomarkers are planned. This assay may have a role both in personalized clinical therapy and in more efficient drug development.

UR - http://www.scopus.com/inward/record.url?scp=84865146617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865146617&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-12-0681

DO - 10.1158/0008-5472.CAN-12-0681

M3 - Article

C2 - 22865459

AN - SCOPUS:84865146617

VL - 72

SP - 3901

EP - 3905

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 16

ER -